Comparative Pharmacology
Head-to-head clinical analysis: ISMO versus NITRO BID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMO versus NITRO BID.
ISMO vs NITRO-BID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing cGMP levels, leading to smooth muscle relaxation and vasodilation.
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
None Documented
None Documented
Clinical Note
moderateVismodegib + Digoxin
"Vismodegib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVismodegib + Digitoxin
"Vismodegib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVismodegib + Deslanoside
"Vismodegib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVismodegib + Acetyldigitoxin
"Vismodegib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator